View this email in your browser
Share Share
Tweet Tweet
Forward Forward


Bringing you our latest news, features and guidance.
October 2021
COVID-19NewsGet involved | Events


Updates to our managing COVID-19 guideline 

On 4 October 2021, we added new recommendations to our managing COVID-19 guideline on the use of:

We have also updated the supporting evidence on use of heparins with the peer reviewed REMAP-CAP trial results. This update does not change our current recommendations.

We are continuously updating this guideline to incorporate the latest evidence and keep abreast of new developments in diagnosing and treating COVID-19. We’ll highlight recent updates in this monthly email communication, or you can keep up to date on the latest live changes through our website.


A bright yellow tent pegged on the kerb

New draft guideline on supporting people experiencing homelessness

The draft guidance aims to help health and social care practitioners to reduce health inequalities for people experiencing homelessness. It highlights that targeted approaches are often needed to ensure that people experiencing homelessness have access to the same standard of health and social care as the general population. We recommend that care should be delivered through specialist multidisciplinary teams which span all sectors of care and be tailored to meet the level of local need.

Illustration of sickle cells in a blood vein

First new treatment in 2 decades for sickle cell disease

Our latest draft guidance recommends crizanlizumab as a treatment option for preventing recurrent sickle cell crises in people aged 16 or over. More than 300 people are expected to benefit from the treatment in the first year, through a managed access agreement, increasing to more than 450 people in subsequent years.

People with advanced or metastatic urothelial cancer to get life-extending treatment

Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will soon be eligible for a new life-extending treatment with atezolizumab. Our final draft guidance follows additional clinical evidence that showed people who have atezolizumab are likely to live up to 8 months longer than those who have platinum-containing chemotherapy.

NICE announces next steps for publication of guideline on ME/CFS

In the coming days, we will publish the updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/ chronic fatigue syndrome (ME/CFS). The announcement follows a roundtable meeting held last week, involving representatives from a range of patient and professional organisations. The meeting addressed concerns raised about some aspects of the guideline.

Catch up on our latest news

Producing our rapid COVID-19 guidelines and the infodemic

In this month's podcast, we talk to Fiona Glen, NICE programme director, centre for guidelines and David Chandler, chief executive of the Psoriasis and Psoriatic Arthritis Alliance on how we worked with stakeholders at the start of the pandemic to produce evidence-based rapid guidelines for COVID-19. We discuss how we ensured the guidelines were informed by the best quality evidence and real-world data, and not adversely influenced by the infodemic.

Get involved

Comment on a consultation

Our current consultations include:

Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
See all our open consultations

Join a committee

We have 2 vacancies for health professionals and lay people to join our committees. Topics include urinary tract infection and maternal and child nutrition. Join us and have an active role in producing a guideline or quality standard.

See all our committee vacancies

Observe a meeting

We’re currently holding all our public meetings virtually. You'll need to register in advance to join. 

Upcoming public meetings:

  • Tuesday 9 November 2021 – Quality standards committee 2 on colorectal cancer
    Registration closes Tuesday 2 November 2021.
    Agenda and register
  • Friday 12 November 2021 – Medical technologies advisory committee on Patch System for treating diabetic foot ulcers
    Registration closes Friday 5 November 2021.
    Agenda and register
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
See all our public meetings


generic picture of a woman looking at a computer screen with headphones on and details of the Zoom event

Attend our next public board meeting

Join us for our next public board meeting on Wednesday 17 November, through Zoom.
Our board meetings are a great opportunity to hear more about the latest developments at NICE.

Register for our public board

unsubscribe from this list